Analysts Set Allena Pharmaceuticals Inc (NASDAQ:ALNA) Price Target at $23.00

Shares of Allena Pharmaceuticals Inc (NASDAQ:ALNA) have received an average recommendation of “Buy” from the nine analysts that are covering the company, MarketBeat reports. One research analyst has rated the stock with a sell recommendation and seven have issued a buy recommendation on the company. The average 1-year target price among analysts that have issued ratings on the stock in the last year is $23.00.

Several brokerages recently issued reports on ALNA. Credit Suisse Group decreased their price target on Allena Pharmaceuticals from $26.00 to $7.00 and set an “outperform” rating for the company in a report on Friday, September 6th. Zacks Investment Research downgraded Allena Pharmaceuticals from a “buy” rating to a “sell” rating in a report on Monday. Wedbush reiterated an “outperform” rating and set a $36.00 price target on shares of Allena Pharmaceuticals in a report on Monday, August 12th. Roth Capital decreased their price target on Allena Pharmaceuticals from $61.00 to $31.00 in a report on Thursday, August 8th. Finally, Cowen reiterated a “buy” rating on shares of Allena Pharmaceuticals in a report on Friday, August 9th.

A number of institutional investors have recently made changes to their positions in ALNA. Sphera Funds Management LTD. grew its holdings in Allena Pharmaceuticals by 24.9% during the first quarter. Sphera Funds Management LTD. now owns 431,193 shares of the company’s stock worth $3,027,000 after buying an additional 85,994 shares in the last quarter. Paloma Partners Management Co bought a new stake in Allena Pharmaceuticals during the second quarter worth $212,000. Susquehanna International Group LLP bought a new stake in Allena Pharmaceuticals during the second quarter worth $137,000. Jane Street Group LLC purchased a new position in Allena Pharmaceuticals in the second quarter worth $116,000. Finally, Wedbush Securities Inc. purchased a new position in Allena Pharmaceuticals in the second quarter worth $63,000. Institutional investors and hedge funds own 65.36% of the company’s stock.

Shares of NASDAQ ALNA remained flat at $$4.29 during midday trading on Monday. The stock had a trading volume of 33,169 shares, compared to its average volume of 76,241. The company has a market capitalization of $100.69 million, a P/E ratio of -2.49 and a beta of 1.91. Allena Pharmaceuticals has a 52-week low of $3.33 and a 52-week high of $11.82. The company’s 50 day moving average is $4.14 and its 200 day moving average is $4.89. The company has a current ratio of 6.80, a quick ratio of 6.80 and a debt-to-equity ratio of 0.22.

Allena Pharmaceuticals (NASDAQ:ALNA) last released its quarterly earnings data on Wednesday, August 7th. The company reported ($0.54) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.53) by ($0.01). Research analysts predict that Allena Pharmaceuticals will post -1.98 earnings per share for the current fiscal year.

Allena Pharmaceuticals Company Profile

Allena Pharmaceuticals, Inc, a late-stage clinical biopharmaceutical company, engages in the development and commercialization of oral enzyme therapeutics to treat patients with rare and severe metabolic, and kidney disorders in the United States and internationally. The company's lead product candidate is reloxaliase, an oral enzyme therapeutic for the treatment of enteric hyperoxaluria, a metabolic disorder commonly associated with kidney stones in adults.

Recommended Story: High-Yield Dividend Stocks

Analyst Recommendations for Allena Pharmaceuticals (NASDAQ:ALNA)

Receive News & Ratings for Allena Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allena Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.